share_log

Morgan Stanley Initiates Coverage On Contineum Therapeutics With Overweight Rating, Announces Price Target of $25

Morgan Stanley Initiates Coverage On Contineum Therapeutics With Overweight Rating, Announces Price Target of $25

摩根士丹利以增持評級啓動對Continueum Therapeutics的報道,宣佈目標股價爲25美元
Benzinga ·  04/30 05:15

Morgan Stanley analyst Jeffrey Hung initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with a Overweight rating and announces Price Target of $25.

摩根士丹利分析師洪傑弗裏以增持評級啓動了對Contineum Therapeutics(納斯達克股票代碼:CTNM)的報道,並宣佈目標股價爲25美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論